Pediatric anesthesia & critical care
CytoSorb haemoadsorption in critically ill children: a multicentre observational study on feasibility, safety, and outcomes, the CYTOPED study
Authors' conclusion
Our data provide some insights into safety and feasibility of CytoSorb® therapy in children.
Study context
- Population
- Critically ill paediatric patients, Italian Children's Hospitals
- Participants
- 62 patients
- Outcome
- Feasibility and use of CytoSorb haemoadsorption
Methodological detailsprospective enrolment, retrospective analysis, Prospective enrolment since February 2021; retrospective analysis February 2018 to February 2021
- Prospective enrolment
- Retrospective analysis
- Prospective enrolment since February 2021; retrospective analysis February 2018 to February 2021
Main finding
As reported in the abstract
- Median PELOD-2 score on Paediatric Intensive Care Unit (PICU) admission (IQR 4;10)
- 7
- Indication sepsis or septic shock, n
- 36
- Applied integrated in a continuous renal replacement therapy (CRRT) circuit
- 87%
- Median time of haemoadsorption (HA), h (IQR 26;72)
- 48
- Median number of cartridges (IQR 1;3)
- 2
- Anticoagulation with heparin
- 76%
- Regional citrate anticoagulation
- 24%
Observational data: associations, not effects.
Safety
- Patients with adverse events
- 12
Original publication
CytoSorb haemoadsorption in critically ill children: a multicentre observational study on feasibility, safety, and outcomes, the CYTOPED study. Ann Intensive Care. Published 30 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →